Key Highlights

  • Mayne Pharma (ASX:MYX) shares finished the 6 November 2026 session at $3.08, up 13.65%, on the same date as its divestment announcement.
  • The company agreed to sell Mayne Pharma International for cash consideration of $55.5 million to Evaris Pharma.
  • Completion is expected in the third quarter of FY27, subject to ACCC approval and customary conditions.

During the Trading session on 6 November 2026, Mayne Pharma Group Limited (ASX:MYX) shares finished at $3.08, up 13.65%, while the S&P/ASX 200 fell 0.49% to 9,020.80. Mayne Pharma is an Adelaide-based specialty pharmaceutical company. The share price move occurred on the same day as its announcement that it had agreed to sell its international segment, which is set out below.

Latest Development: Binding Sale Agreement (6 November 2026)

On 6 November 2026, Mayne Pharma announced that it had entered into a binding share sale agreement with an entity owned by General Pharma Bidco Pty Ltd, the vehicle for Evaris Pharma, for the sale of Mayne Pharma International Pty Ltd. Cash consideration is $55.5 million, payable at completion and subject to customary Working Capital adjustments.

The headline consideration represents 0.79 times FY26 Revenue of $70.7 million for the international Business and 12.1 times its FY26 direct contribution of $4.6 million. The transaction is not subject to Foreign Investment Review Board approval but requires ACCC approval.

Latest Development: Supply and Licence Arrangements

The parties have also agreed the terms of a supply agreement and a transitional Brand licence. Mayne Pharma said the sale completes its transition to a specialty pharmaceutical company focused 100% on the United States. Completion is expected in the third quarter of FY27.

About the Company

Mayne Pharma develops and markets specialty pharmaceutical products, with its operations now focused on the United States market following the proposed divestment. The company holds a range of generic and specialty medicines.

Sector Context

Pharmaceutical companies periodically sell non-core businesses to focus on higher-value markets, and such transactions often rely on multiples of revenue or Earnings contribution. Regulatory approval, including from competition regulators, is a standard step in these sales.

Risks to Watch

Completion depends on ACCC approval and other customary conditions, so the timing or terms could change. Working capital adjustments will affect the final cash received. Following the sale, the company will rely more heavily on its United States operations, which carry their own pricing and regulatory pressures.

Catalysts on Watch

Investors will be watching for ACCC approval, the completion date and how the cash proceeds will be used. Updates on the supply and transitional licence arrangements, and on the United States business in the next reporting period, will also be relevant.